AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06593015 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Radiological tool for the diagnosis of myosteatosis
Description: Calculation of muscle attenuation at L3/L4 CT scan for each patients and evaluation of the relationship between muscle attenuation values and survival
Study NCT04215731 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy with mFOLFOXIRI plus bevacizumab
Description: Bevacizumab (5 mg/kg on day 1) plus mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles and mFOLFOXIRI (oxaliplatin 85 mg/m2, irinotecan 150 mg/m2, and folinic acid 400 mg/m2 followed by 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 2 cycles
Study NCT04215731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Restaging
Description: Restaging by pelvic magnetic resonance imaging (MRI)
Study NCT04215731 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concomitant Chemoradiotherapy
Description: Concomitant chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)
Study NCT04215731 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Radical surgery (TME or more extended surgery)
Study NCT04215731 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Radical surgery (TME or more extended surgery)
Study NCT04215731 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (only when patients with MRF involved or ycT4a/b by restaging)
Description: Chemoradiotherapy (preoperative radiotherapy consisted of 50 Gy in 25 fractions, and concurrent with capecitabine at a fixed dose of 825 mg/m2 twice daily on days 1 to 5 for 5 weeks)
Study NCT04215731 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Induction chemotherpay with FOLFOX
Description: mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) for 4 cycles
Study NCT02514083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420mg PO daily for the duration of the study.
Study NCT02514083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day IV on days 1-5 of cycles 3 and 4
Study NCT04167657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: Sintilimab 200mg IV, every 3 weeks, until progressive disease (PD), intolerable toxicity, or at a maximum of 24 months.~Before enrollment, patient should undergo radiation no less than dose 30Gy( 6 Gy × 5, or other ), or the planned dose could reach 30 Gy. Sintilimab shall be started no later than 3 weeks after radiation. Radiotherapy can be performed on the same day as sintilimab.
Study NCT06084026 — intervention group
Intervention type: OTHER
Intervention: ActivPal
Description: Participants will wear the activity meter (a small button like device) on their thigh for a period of 7 days at the following time-points: baseline, 6, 12, 18, 24, 30 and 36 months. The meter will be placed on their thigh at a research visit and mailed back to the study team after 7 days.
Study NCT03294707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG10 oral tablet
Description: Active single ascending dose
Study NCT03294707 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo single dose
Study NCT03894124 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Doravirine
Description: Non-nucleoside reverse transcriptase inhibitor. Administered as film coated tablet.
Study NCT02231515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective laser trabeculoplasty (SLT)
Description: Selective laser trabeculoplasty
Study NCT02231515 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pattern laser trabeculoplasty (PLT)
Description: Pattern laser trabeculoplasty (PLT)
Study NCT04567628 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: As this was an observational study, no intervention was administered.
Study NCT03609645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Fascia iliaca block
Description: FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)
Study NCT03609645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Femoral articular branches block(FAB)
Description: FIB Placebo Block: 20mL of Normal Saline Active drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400, 000)~FAB block Placebo Block: 20mL of Normal Saline Active Drug: 20mL of 0.25% Bupivacaine with epinephrine (1:400,000)
Study NCT04174417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: systolic blood pressure (SBP)
Description: Systolic blood pressure (SBP) 80-90 mmHg remifentanil infusion was applied to Group 1 patients. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory
Study NCT04174417 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mean blood pressure (MBP)
Description: For group 2, remifentanil infusion was performed with a mean blood pressure (OCD) of 50-65 mmHg. In addition to remifentanil infusion, 0.002 μg.kg of glycerol trinitrate (Perlinganit) was administered as an intermittent bolus in patients who needed to achieve target blood pressure. All patients received 5-8 ml / kg / h IV infusion of balanced electrolyte solution (Isolyte-S) during the operation.~Hemodynamic parameters (HR, SBP, OCD), BIS, SpO2 and NIRS were recorded at 5 minute intervals. At the end of the operation, 3 ml of blood was taken from the untreated arm of all patients to the HIF1a, TAS and TOS values and sent to the biochemistry laboratory.
Study NCT03401801 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stellate ganglion block
Description: Well trained pain physician performs all the ultrasound(US)-guided stellate ganglion block(SGB)s, who is not involved in evaluating study variables. Electrocardiography, noninvasive blood pressure, heart rate, and peripheral oxygen saturation were monitored for all patients before, while, and after conducting procedure. For US-guided SGB, patients are supine positioned, and skin preparation on injection site is done with chlorohexidine. Procedure is conducted under ultrasound guidance at C6 level. 4 ml, 6 ml, and 8 ml of 1% lidocaine is injected for the each group, respectively.
Study NCT05684835 — intervention group
Intervention type: PROCEDURE
Intervention: Excision
Description: All patients underwent surgery under general anesthesia and intraoperative neuromonitoring according to the preoperatively predicted NO. Using an anterior cervical approach, the tumor was delineated after identifying the relationships among the great vessels, nerves, and tumors. The NO was confirmed intraoperatively. Sharp dissection was performed meticulously to enucleate the tumor from the NO to preserve most nerve fibers.
Study NCT03562364 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AlterG anti-gravity treadmill
Description: The AlterG treadmill is an FDA approved device that allows patients to perform early partial weight bearing exercises in a tightly controlled and safe environment
Study NCT03117010 — intervention group
Intervention type: DRUG
Intervention: Steroids
Description: High dose dexamethasone 20 mg PO or IV
Study NCT03117010 — intervention group
Intervention type: DRUG
Intervention: Etoposide
Description: Etoposide 150mg/BSA
Study NCT01929421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/S-1
Study NCT02167971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active Coil
Description: The patients will undergo 10 sessions (2,000 pulses each, lasting 20 minutes) of repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex with the following parameters: 10Hz, 50 trains (40 pulses on each train), biphasic wave, 25 seconds between the trains.
Study NCT02167971 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
Study NCT00364637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevoflurane (Volatile Anesthetic)
Study NCT00364637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Total intravenous anesthesia
Study NCT02266368 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Antimicrobeal coated stents
Description: Patients in the intervention arm will undergo placement of (Silver Sulphdiazine) antimicrobeal coated stents
Study NCT02931877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sevoflurane
Study NCT02931877 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: propofol
Study NCT03072407 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PB-119 injection
Study NCT03072407 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: PB-119 injection placebo
Study NCT03998306 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Probiotics
Description: the participants will receive probiotic lozenge before falling asleep for 12 weeks.~the participants will receive dietetic and hygienic instructions
Study NCT03998306 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No intervention
Description: No intervention
Study NCT02088008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cinidipine, valsartan
Study NCT02088008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cinidipine, valsartan
Study NCT01131507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EUR-1008 (APT-1008)
Description: EUR-1008 (APT-1008) (Zenpep® \[pancrelipase\] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
Study NCT01977547 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Short storage RBC age
Description: IND obtained to cover the expiration date on the red blood cell unit
Study NCT00144807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00144807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Study NCT00144807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00144807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Study NCT02130817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.
Study NCT02130817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus withdrawal
Description: Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.
Study NCT02130817 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasmapheresis/Intravenous Immunoglobulin G
Description: Enrolled patients will start with standard of practice treatment including plasmapheresis and IVIG therapy twice after transplant, on days 2 and 4 and potentially once before transplant. Plasmapheresis and albumin exchange for one volume of blood will be performed in the infusion center at the University of Wisconsin Hospital and Clinics (UWHC). Each pheresis session will be completed by IVIG infusion. While plasmapheresis will help with the removal of circulating Donor Specific Antibodies (DSA), IVIG therapy will provide immunomodulatory characteristics that include sterilizing immunity from infections, inhibiting and scavenging activated complement fragments, modifying cell-mediated immune responses, inducing regulatory T cells and importantly, inhibiting deleterious antibody production.
Study NCT02130817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymoglobulin (ATG)
Description: Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.
Study NCT02130817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Myfortic
Description: Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
Study NCT02130817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids
Description: Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
Study NCT00992108 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Description: 1cc 1%
Study NCT00992108 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemodenervation
Description: botulinum toxin
Study NCT04602221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet, Film-coated tablet
Study NCT03902431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ABCS training
Description: Clinicians and patients will be given information regarding the ABCS (Aspirin, Blood Pressure control,Cholesterol control, and Smoking Cessation) and for reducing CVD risk among HIV patients.
Study NCT03916770 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vibrator
Description: The Sham control group will have WBV the same time,in the same position with the same frequency but 99.5% weakened amplitude.
Study NCT03916770 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Real vibrator
Description: The intervention group will have WBV(frequency:30Hz,amplitude:2,2mm,at upright position
Study NCT00593216 — intervention group
Intervention type: DEVICE
Intervention: Functional MRI imaging
Description: The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.
Study NCT02208310 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 10,000 IU
Description: Cholecalciferol 10,000 IU po daily
Study NCT02208310 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol 400 IU
Description: Cholecalciferol 400 IU po daily
Study NCT04424095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: In-office vascular visit
Description: The patient will be examined to search for signs or symptoms of chronic venous disease (teleangiectasia, reticular veins, varicose veins, skin changes, pain, itching, heavy legs, ankle edema)
Study NCT04424095 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Echo Duplex of lower limbs
Description: The venous system of lower limbs will be checked in order to detect any vein dilation and reflux.
Study NCT01708200 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Memory Intervention
Description: A comparison of two type of memory intervention protocols; a psychoeducational/intervention protocol versus a computerized memory protocol in a population of individuals with mental illness.
Study NCT02783534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Description: Participants allocated to VA group will receive traditional acupuncture treatment on the Guanyuan(RN 4), bilateral Sanyinjiao(SP 6), bilateral Zigong(EX-CA1), bilateral Xuehai(SP 10). Additional points will be chosen according to TCM syndrome differentiation constitution of patients. If patients with deficient syndrome, bilateral Zusanli (ST 36) will be included. If patients with sufficiency syndrome, bilateral Diji (SP 8) will be included. The NO.16 special type of acupuncture needle (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi.
Study NCT02783534 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: We use a non-insertive sham control produced by Asia-med Company in Germany-the streitberger placebo-needle. Sham points are described as follows: 1) 5 inch lateral to the seventh thoracic spine; 2) 5 inch lateral to the eighth thoracic spine; 3) 5 inch lateral to the ninth thoracic spine; and 4) 5 inch lateral to the tenth thoracic spine.
Study NCT02783534 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Usual care
Description: Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.
Study NCT02783534 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.
Study NCT02783534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual care
Description: Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.
Study NCT02364700 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hand of Hope (HOH)
Description: Subjects will receive arm training 3x/week for 6 weeks, each session is anticipated to last approximately 60 minutes. Sessions will be scheduled for Monday, Wednesday, and Friday whenever possible to provide a rest period between sessions. Each session will consist of the following:~* warm up-passive stretch of hand in flexion and extension (5 minutes);~* setting the EMG threshold parameters for the device;~* active practicing of opening the hand (Desperate Bee, Hungry Bird, Sun Archer games; 10 min)~* active practice of closing then hand (UFO Catcher game; 10 min)~* open and closing the hand (Ball and Basket game; 10 min)~* open and closing the hand while incorporating reach ( for subjects with adequate ability to reach with shoulder/elbow; 10 min)~* cool down-passive stretch of hand in flexion and extension (5 minutes)
Study NCT03123692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emeramide
Description: Lipophilic, membrane passing Metal chelator and anti oxidant
Study NCT03123692 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 14 days treatment with placebo
Study NCT03673800 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental Group
Description: Cognitive web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
Study NCT03673800 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: Sensorial web-based training : 2 up to 30 minutes sessions a week during 6 weeks. Optional debriefing by a neuropsychologist up to 15 minutes twice a week
Study NCT03307109 — intervention group
Intervention type: OTHER
Intervention: Quality of life
Description: Patients will complete two EQ-5D-5L and EQ-5D-3L quality of life questionnaires and will complete an analog visual scale during each of their follow-up visits to the Infectious and Tropical Diseases Department of Croix-Rousse hospital. No visits will be added to complete the questionnaires.
Study NCT00055393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: 18 subjects in this randomly controlled double blind study received bupropion.
Study NCT00055393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 21 subjects received Placebo.
Study NCT02626312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02626312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Correlative studies
Study NCT02626312 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02626312 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT00751582 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Food supplementation and nutrition education
Description: Food supplementation and nutrition education for three months